Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, 210029 Nanjing, China.
Breast Cancer Res Treat. 2010 Aug;123(1):265-70. doi: 10.1007/s10549-010-0759-5. Epub 2010 Feb 4.
The Catechol-O-methyltransferase (COMT) plays an important role in the development of breast cancer. Many previous epidemiologic studies explored the association of COMT Val158Met polymorphism with breast cancer susceptibility. However, the results were inconsistent. We therefore performed a meta-analysis of 26 published studies including 16,693 breast cancer patients and 18,261 healthy controls. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association of the COMT Val158Met polymorphism with breast cancer risk. No significant association was found in all genetic models in overall, Asian, European populations. After the studies whose genotype frequencies in the controls did not fulfill Hardy-Weinberg equilibrium were excluded, we found a borderline significant decreased breast cancer risk among Europeans (for the recessive model LL versus HH/HL: OR = 0.90, 95% CI = 0.90-1.00, P (heterogeneity) = 0.33). There was no between-study heterogeneity. In conclusion, COMT Val158Met polymorphism may be a low-penetrant risk factor for breast cancer development in European population.
儿茶酚-O-甲基转移酶（COMT）在乳腺癌的发生发展中起着重要作用。许多先前的流行病学研究探讨了 COMT Val158Met 多态性与乳腺癌易感性的关系。然而，结果并不一致。因此，我们对 26 项已发表的研究进行了荟萃分析，这些研究包括 16693 名乳腺癌患者和 18261 名健康对照者。使用粗比值比（OR）和 95%置信区间（CI）来评估 COMT Val158Met 多态性与乳腺癌风险之间的关联强度。在所有遗传模型中，总体人群、亚洲人群和欧洲人群均未发现明显相关性。在排除对照组基因型频率未满足 Hardy-Weinberg 平衡的研究后，我们发现欧洲人群中存在乳腺癌风险的边缘显著降低（对于隐性模型 LL 与 HH/HL：OR = 0.90，95%CI = 0.90-1.00，P（异质性）= 0.33）。研究之间没有异质性。综上所述，COMT Val158Met 多态性可能是欧洲人群乳腺癌发生的低外显率风险因素。
Zotero 插件